Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914498 | 0.89 | KDM4E (0.41) | MAPTS1PR2HSD17B10KMT2ATSHR | |
| SCHEMBL23914489 | 0.85 | SLC16A3 (0.33) | MAPTHSD17B10KMT2AALOX15TSHR | |
| SCHEMBL23908911 | 0.85 | MAPT (0.45) | MAPTS1PR2AKR1B1POLBHSD17B10 | |
| SCHEMBL23915534 | 0.85 | PTGDR2 (0.39) | AKR1B1PTGDR2 | |
| SCHEMBL23914582 | 0.84 | MAPT (0.44) | MAPTS1PR2AKR1B1POLBHSD17B10 | |
| SCHEMBL23915456 | 0.84 | AKR1B1 (0.38) | MAPTS1PR2AKR1B1PTGDR2CMA1 | |
| SCHEMBL23915295 | 0.83 | CNKSR1 (0.35) | SLC16A3 | |
| SCHEMBL23915526 | 0.80 | S1PR2 (0.46) | S1PR2HSD17B10KMT2AALOX15PTGDR2 | |
| SCHEMBL23914832 | 0.78 | ALDH1A1 (0.36) | MAPTHSD17B10KMT2ATSHR | |
| SCHEMBL23660727 | 0.74 | GLS (0.33) | POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | MAPT 4876/4885S1PR2 3/4885AKR1B1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.